

**Remarks:**


This is in response to the restriction requirement mailed May 10 2004 for the above application. Claims 1 and 3-10 are pending in the application.

Applicants elect with traverse the species 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8- diaza-naphthalene, disclosed in the specification and claimed in Claim 4 of the present application. The Examiner's restriction requirement is traversed since it is respectfully submitted that all claims originally submitted may be examined without undue burden on the Examiner.

Please charge the extension fee and any other appropriate fee to cover this submission to Pfizer Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: May 14 2004

  
\_\_\_\_\_  
Andrea Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer, Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-1898